Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| SGMT | INST-CLUSTER | bullish | 4/10 | A strong institutional cluster emerged in SGMT during Q2 2026, with 23 buyers accumulating $22.6M in net new positions v | Sep 22, 2026 |
| CRDF | INST-CLUSTER | bearish | 4/10 | Institutional activity in CRDF during Q2 2026 was sharply divided: 15 buyers added $1.6M in new positions (led by Jane S | Sep 22, 2026 |
| GEVO | INST-CLUSTER | bearish | 4/10 | In Q2 2026, 16 institutions added to GEVO positions (aggregate current value $6.7M, net change -$1.0M) while 12 trimmed | Sep 22, 2026 |
| PALI | INST-CLUSTER | mixed | 4/10 | In Q2 2026, 15 institutional buyers accumulated $43.1M in PALI shares while 9 sellers reduced by $13.2M, resulting in a | Sep 22, 2026 |
| LRMR | INST-CLUSTER | bearish | 4/10 | Larimar Therapeutics saw a mixed institutional cluster in Q2 2026: 38 buyers (mostly mega-passive index funds) added $5. | Sep 22, 2026 |
| CAMP | INST-CLUSTER | neutral | 3/10 | Camp4 Therapeutics Corp (CAMP) saw a strong institutional accumulation cluster in Q2 2026, with 11 buyers adding $9.1M i | Sep 22, 2026 |
| IVVD | INST-CLUSTER | mixed | 3/10 | Institutional activity in IVVD during 2026-Q2 was mixed: 19 buyers added $1.9M in new holdings (led by Citadel, Morgan S | Sep 22, 2026 |
| CNTN | INST-CLUSTER | neutral | 3/10 | A strong institutional cluster formed in CNTN during 2026-Q2, with 13 buyers accumulating $19.2M in net new holdings (do | Sep 22, 2026 |
| GOSS | INST-CLUSTER | mixed | 4/10 | In Q2 2026, a cluster of 32 institutional buyers accumulated $8.5M in Gossamer Bio (GOSS) while 17 sellers reduced holdi | Sep 22, 2026 |
| GRML | INST-CLUSTER | neutral | 2/10 | Five passive/index institutions (Geode, Northern Trust, Vanguard, LPL Financial, State Street) added GRML positions in Q | Sep 22, 2026 |
| LODE | INST-CLUSTER | neutral | 3/10 | Institutional cluster in LODE shows heavy passive buying (10 buyers, net +$29.2M) concentrated in mega-passive funds (Bl | Sep 22, 2026 |
| NMRA | INST-CLUSTER | neutral | 3/10 | In Q2 2026, 21 institutional buyers accumulated $15.2M in NMRA while 10 sellers reduced by $10.0M, resulting in a net $5 | Sep 22, 2026 |
| CLYM | INST-CLUSTER | neutral | 3/10 | 22 institutional buyers accumulated $165.0M in net new Climb Bio positions during Q2 2026, overwhelmingly dominated by m | Sep 22, 2026 |
| SION | INST-CLUSTER | mixed | 3/10 | Institutional activity in SION during Q2 2026 was mixed: 25 buyers added $35.7M in net new holdings (dominated by mega-p | Sep 22, 2026 |
| CTKB | INST-CLUSTER | mixed | 4/10 | In Q2 2026, institutional activity in Cytek Biosciences (CTKB) was sharply mixed: 20 buyers added $21.5M in holdings (le | Sep 22, 2026 |
| CTMX | INST-CLUSTER | mixed | 3/10 | A large institutional cluster in CytomX Therapeutics (CTMX) shows 28 buyers accumulating $26.3M in new positions versus | Sep 22, 2026 |
| PRLD | INST-CLUSTER | bullish | 4/10 | A strong institutional accumulation cluster emerged in PRLD during Q2 2026, with 14 buyers adding $27.0M in net new hold | Sep 22, 2026 |
| CYPH | INST-CLUSTER | neutral | 3/10 | Ten institutional investors, predominantly mega-passive index funds, accumulated $2.3M in CYPH during Q2 2026, while two | Sep 22, 2026 |
| AURA | INST-CLUSTER | neutral | 3/10 | A cluster of 25 institutional buyers added $29.4M in AURA positions during Q2 2026, led by Vanguard (+$19.5M) and Geode | Sep 22, 2026 |
| ATYR | INST-CLUSTER | bearish | 4/10 | Institutional activity in ATYR during Q2 2026 shows a stark divergence: mega-passive index funds (Fidelity, UBS, Geode, | Sep 22, 2026 |
| DTIL | INST-CLUSTER | neutral | 3/10 | In Q2 2026, 17 institutional buyers accumulated $15.7M net in Precision Biosciences (DTIL), overwhelmingly driven by meg | Sep 22, 2026 |
| CGEM | INST-CLUSTER | bullish | 4/10 | CGEM saw strong institutional accumulation in Q2 2026, with 26 buyers adding $68.3M in net new holdings (led by T. Rowe | Sep 22, 2026 |
| ASND | INST-CLUSTER | bearish | 4/10 | 32 tracked institutions completely exited their ASND positions in Q2 2026, liquidating $2.41B in aggregate holdings. The | Sep 22, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's Laboratories filed a Form 6-K on September 22, 2026, to notify exchanges of a Board meeting scheduled for Oc | Sep 22, 2026 |
| JUNS | SC 13G | neutral | 4/10 | PharmAla Biotech Holdings Inc. disclosed a 17.3% passive stake in Jupiter Neurosciences via a Schedule 13G filed Septemb | Sep 22, 2026 |
| MEOH | 6-K | bullish | 5/10 | Methanex announced a partial redemption of US$300 million of its 5.125% senior notes due 2027, with a redemption date of | Sep 22, 2026 |
| GSK | 6-K | neutral | 2/10 | GSK plc filed a Form 6-K reporting open-market purchases of ordinary shares and American Depositary Shares by its Non-Ex | Sep 22, 2026 |
| HBIO | SC 13G/A | neutral | 3/10 | Leviticus Partners LP filed an amended Schedule 13G disclosing a 5.2% passive stake in Harvard Bioscience Inc as of Sept | Sep 22, 2026 |
| OPTH | 6-K | neutral | 3/10 | Optimi Health appointed Dr. Michael Blough as Chief Clinical Development Officer, a newly created role overseeing the co | Sep 22, 2026 |
| AIM | PRESS-RELEASE | neutral | 3/10 | AIM ImmunoTech CEO issued a letter to shareholders addressing the recent FDA approval of daraxonrasib for pancreatic can | Sep 22, 2026 |